| Nov 18 |
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
|
| Nov 13 |
Telix ADSs Commence Trading on Nasdaq
|
| Nov 13 |
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
|
| Nov 3 |
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
|
| Oct 30 |
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
|
| Oct 23 |
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
|
| Oct 22 |
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
|
| Oct 17 |
Telix Files Form 20-F Registration Statement for Nasdaq ADS
|
| Oct 17 |
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
|
| Oct 7 |
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
|
